Published in Medical Letter on the CDC and FDA, November 14th, 2010
The approval was based on results from the DASISION (Dasatinib versus Imatinib Study in Treatment-Naive CP-CML Patients) open-label, Phase 3 trial, which were published in the New England Journal of Medicine and presented as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.